Sofwave Medical's 2024 Financial Growth: A Closer Look
Strong Financial Performance in 2024
Sofwave Medical Ltd (TASE: SOFW), a pioneering company in the non-invasive aesthetic medical device sector, recently reported impressive preliminary financial results for the fourth quarter and the entire fiscal year. With products that enhance treatments for practitioners globally, Sofwave truly stands out in the market.
Fourth Quarter Highlights
The company anticipates its revenue for the fourth quarter of 2024 to fall between $18.2 million and $18.4 million, marking a remarkable growth of approximately 20% compared to roughly $15.3 million during the same period in 2023. This growth reflects the increasing demand for its innovative aesthetic technologies.
Full Fiscal Year Performance
In terms of overall fiscal performance, Sofwave expects its total revenue for the full year 2024 to be between $59.5 million and $59.7 million, an expansion from $50.3 million in the previous year, indicating a steady rise of about 19%. This upward trend showcases the company’s effectiveness in catering to the expanding market for aesthetic medical devices.
Financial Stability
As of December 31, 2024, Sofwave reported approximately $21.6 million in cash and cash equivalents, a slight increase from $21.2 million on September 30, 2024. This demonstrates the company's solid financial management and ability to sustain growth amidst rising operational demands.
About Sofwave Medical
Sofwave Medical Ltd, known for its revolutionary approach to wrinkle reduction and skin lifting procedures, leverages its proprietary SUPERB™ technology. This Synchronous Ultrasound Parallel Beam technology, which has received FDA clearance, effectively addresses facial wrinkles and improves skin laxity in various areas, including beneath the chin and on the upper arms. The innovative Pure Impact™ module uses electrical muscle stimulation technology approved for muscle toning, offering practitioners safe and effective treatment options.
Contact Information
For further inquiries, you can reach out to Sofwave Medical or their investor relations team. Interested parties may contact:
General Contact
Email: Info@sofwave.com
Investor Relations
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
Email: britchie@lifesciadvisors.com
Frequently Asked Questions
What is Sofwave Medical known for?
Sofwave Medical specializes in non-invasive aesthetic medical devices that improve skin quality and appearance.
What were Sofwave's revenue expectations for 2024?
For 2024, Sofwave expects its revenue to be between $59.5 million and $59.7 million.
How much cash did Sofwave have at the end of 2024?
As of December 31, 2024, Sofwave reported approximately $21.6 million in cash and cash equivalents.
What technology does Sofwave utilize in its treatments?
Sofwave uses its patented SUPERB™ technology, which is FDA-cleared for various aesthetic treatments.
Who can I contact for more information about Sofwave?
You can contact Sofwave's general information email at Info@sofwave.com or reach out to their investor relations via Brian Ritchie from LifeSci Advisors LLC.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.